FDA grants GE Healthcare priority review for AdreView

06/12/2008 | Reuters

The FDA has granted GE Healthcare priority review for its application for a molecular-imaging agent called AdreView, used in detecting neuroendocrine tumors. The imaging agent has been in development since 2004 and the new drug application for it was accepted by the FDA last month.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC